Based on our previous studies showing that inclusion of a tumor antigen within VSV induces CD8+ T cell dependent anti-tumor therapy directed specifically against the virally encoded antigen19, 34, 35, 36, we hypothesized that it would be possible to amalgamate the potent anti-viral response with an anti-tumor T cell response by expressing immunologically relevant tumor associated antigens from within the virus. The gene discussed is CD8A; the disease is neoplasm.